全麻快速顺序诱导中最佳催眠药物选择:三臂优效性开放标签随机对照试验(主要结局盲法评估)的研究方案(HyPnotiKs研究)
本研究为多中心、开放标签、优效性随机对照试验,比较氯胺酮(2 mg/kg)、丙泊酚(2 mg/kg)与氯胺酮-丙泊酚等摩尔合剂(各1 mg/kg)用于成人全麻快速顺序诱导,主要结局为首次插管成功且无严重低血压的比例,计划纳入1218例,2025年4月在法国20个麻醉单位启动入组,预计2027年5月完成随访。
要点
- 研究旨在证明氯胺酮或氯胺酮-丙泊酚合剂在快速顺序诱导中减少低血压方面优于丙泊酚。
- 主要结局为首次气管插管成功且无严重低血压的比例,采用分层检验比较三组。
- 计划纳入1218例成人全麻手术需气管插管且存在胃内容物误吸风险的患者。
核心结论
- 该研究旨在证明与丙泊酚相比,氯胺酮或氯胺酮-丙泊酚合剂联合神经肌肉阻滞剂用于全麻快速顺序诱导时,在不发生低血压的情况下实现气管插管方面具有优效性。
- 该研究是首个以首次气管插管成功且无低血压为主要结局、比较氯胺酮、氯胺酮-丙泊酚合剂或丙泊酚作为饱胃患者快速顺序诱导首选催眠药的随机对照试验。
研究设计与样本
- 多中心、开放标签、优效性随机对照试验,主要结局采用盲法评估。
- 比较氯胺酮(2 mg/kg)、丙泊酚(2 mg/kg)和氯胺酮-丙泊酚等摩尔合剂(各1 mg/kg)用于快速顺序诱导。
- 计划纳入1218例成人全麻手术需气管插管且存在胃内容物误吸风险的患者。
- 2025年4月在法国20个麻醉单位启动入组,预计最终随访日期为2027年5月。
- 采用分层检验程序比较三组,按意向性治疗原则分析。
关键数值与推荐
- 主要结局为首次气管插管成功且无严重低血压的比例。
- 氯胺酮剂量为2 mg/kg,丙泊酚剂量为2 mg/kg,氯胺酮-丙泊酚合剂为氯胺酮1 mg/kg与丙泊酚1 mg/kg。
临床怎么用
- 该研究方案已获南地中海V区个人保护委员会伦理批准,并将按照赫尔辛基宣言和药物临床试验质量管理规范原则实施。
- 研究结果将通过科学会议报告和同行评议期刊发表进行传播。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Propofol is the most frequently used hypnotic during rapid sequence induction in patients at risk of pulmonary aspiration of gastric contents worldwide. Its most common side effect is to induce hypotension due to dose-dependent vasoplegia. Ketamine is an alternative with pharmacological hemodynamic stability but a higher risk of postoperative delirium. Ketofol, an equimolar combination of these two hypnotics, has recently been proposed in this setting. The objective of this study is to demonstrate the superiority of ketamine (or ketofol) compared to propofol, in association with a neuromuscular blocking agent, for achieving tracheal intubation without hypotension in patients undergoing surgery under general anesthesia and at risk of pulmonary aspiration of gastric contents. METHODS: The HyPnotiKs study is a multicenter, open-labeled, superiority, randomized controlled trial comparing ketamine (2 mg/kg), propofol (2 mg/kg), and ketofol (1 mg/kg each) for rapid sequence induction in 1218 adult surgical patients requiring tracheal intubation during general anesthesia. Enrollment started in April 2025 in 20 French anesthesia units. The expected date of the final follow-up is May 2027. The primary outcome is the proportion of successful tracheal intubation at the first attempt and without major hypotension. A hierarchical procedure is planned to compare the three arms. Intention-to-treat principle will be applied. DISCUSSION: The HyPnotiKs study protocol has been approved by the ethics committee of the Comité de Protection des Personnes Sud Méditerranée V and will be carried out in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. The results of this study will be disseminated through presentations at scientific conferences and publications in peer-reviewed journals. The HyPnotiKs study is the first randomized controlled trial powered to investigate whether ketamine, ketofol, or propofol is the hypnotic of first choice for rapid sequence induction of anesthesia in patients with a full stomach, considering successful tracheal intubation without hypotension. TRIAL REGISTRATION: ClinicalTrials.gov NCT06733129. Registered on December 2024.
引用
- Grillot N, Volteau C, Quillet P, et al. Best hypnotic drug choice for rapid sequence induction in the operating room: study protocol for a 3-arm superiority open-labeled randomized controlled trial with blinded evaluation of the primary outcome (the HyPnotiKs study). Trials. 2026. PMID: 41546091. doi:10.1186/s13063-026-09452-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。